A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

This study is comparing two chemotherapy approaches for older patients with a blood cancer called mantle cell lymphoma. One group receives a standard two-drug regimen (rituximab and bendamustine), while the other alternates between that regimen and a three-drug combination that includes cytarabine. The goal is to find which approach works better for patients who are not able to tolerate intensive stem cell transplants. **You may be eligible if...** - You have been newly diagnosed with mantle cell lymphoma and have not been treated before - You are 70 or older, or between 60-69 and not a candidate for high-dose therapy with stem cell transplant - You are in reasonably good physical condition - Your heart, kidneys, liver, and blood counts are at adequate levels **You may NOT be eligible if...** - You have very early stage (Stage 1) disease or non-invasive (in-situ) mantle cell lymphoma - You have had prior treatment for lymphoma in the last 5 years - You have another active cancer (with some exceptions) - You have cancer in your brain or spinal fluid - You have active hepatitis B, hepatitis C, or HIV - You have serious heart, lung, neurological, or infectious conditions Talk to your doctor to see if this trial is right for you.